SCHEMBL13097510

SCHEMBL13097510

Cc1c(COCCCCOc2ccc(F)cc2)[nH]c2ccccc2c1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 7/20 0.61
CTSV O60911 2/20 0.41
CTSL P07711 2/20 0.41
SIGMAR1 Q99720 1/20 0.41
MCL1 Q07820 3/20 0.40
HTR1A P08908 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39
DRD3 P35462 1/20 0.39
KCNH2 Q12809 1/20 0.39
HCAR2 Q8TDS4 1/20 0.39
HTT P42858 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13097508 0.91 CYP2D6 (0.66) CYP2D6CTSVCTSLMCL1HTT
SCHEMBL13349850 0.89 CYP2D6 (0.61) CYP2D6CTSVCTSLMCL1HTT
SCHEMBL3103934 0.87 CYP2D6 (0.56) CYP2D6CTSVCTSLSIGMAR1MCL1
SCHEMBL3092224 0.87 CYP2D6 (0.59) CYP2D6CTSVCTSLMCL1HTT
SCHEMBL3094863 0.85 CYP2D6 (0.57) CYP2D6CTSVCTSLMCL1HCAR2
SCHEMBL13097506 0.82 CYP2D6 (0.55) CYP2D6HTTKDM4EALDH1A1GLA
SCHEMBL13097555 0.82 CYP2D6 (0.67) CYP2D6CTSVCTSLHTTKDM4E
SCHEMBL13097496 0.82 CYP2D6 (0.64) CYP2D6CTSVCTSLHTTKDM4E
SCHEMBL13097503 0.81 CYP2D6 (0.58) CYP2D6DRD2DRD3
SCHEMBL13097582 0.81 CYP2D6 (0.54) CYP2D6HTTKDM4EALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367702-B2 Quinolone derivative ASTELLAS PHARMA INC. (JP) 2013-02-05 US disclosed
US-8367702-B2 Quinolone derivative ASTELLAS PHARMA INC. (JP) 2013-02-05 US disclosed
US-20100256113-A1 QUINOLONE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2010-10-07 US disclosed
US-20100256113-A1 QUINOLONE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2010-10-07 US disclosed
EP-2194044-A1 QUINOLONE DERIVATIVE Astellas Pharma Inc. (JP) 2010-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256113-A1 QUINOLONE DERIVATIVE NQO1, NQO2, NADK CYP2D6 230/4885CTSV 1341/4885CTSL 1938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.